- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03473522
Effects of tDCS Combined With Therapeutic Exercises in Patients With Parkinson's Disease.
April 30, 2021 updated by: Alessandra Tanuri Magalhães
Effects of Transcranial Direct Current Stimulation Combined With Therapeutic Exercises in Patients With Parkinson's Disease: Randomized Clinical Trial
Parkinson's disease is a progressive, degenerative neurological disease associated with profound changes in the quality of life of its survivors.
Therapeutic exercises are widely employed in the attempt to delay or minimize disease progression, characterized by significant motor and sensory deficits.
Recent evidence has demonstrated the potential use of transcranial direct current stimulation (TDCs) as a complement to therapeutic exercises.
However, few studies have investigated the effects of TDCs combined with therapeutic exercises in patients with Parkinson's disease.
This study aims to investigate the effect of TDCs combined with therapeutic exercises in people with Parkinson's disease.
Thirty patients will be randomized into two distinct groups to receive either TDCs(anodal) + therapeutic exercises or TDCs (sham) + therapeutic exercises for 24 sessions over a five-week period.
The primary clinical outcome (balance) and secondary outcomes (functional capacity, quality of life and perception of overall effect) will be collected before treatment after two and five weeks at month 3 and month 6 after randomization.
The data will be collected by a blind examiner to the treatment allocation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In this study, a randomized, double-blind, placebo-controlled experimental design will be used.
The 30 participants will be randomized into two groups: (1) TDCs(anodal) + therapeutic exercises and (2) TDCs (sham) + therapeutic exercises.
The treatment will be performed for 8 weeks, with three sessions per week, totaling 24 sessions of electrostimulation and therapeutic exercises.
The primary variable (balance), secondary outcomes and other outcomes will be assessed before and after treatment.
Follow-up of patients will be conducted at 8, 12 and 24 weeks after randomization.
All evaluations will be performed by a single researcher who, like the patients, will not know which stimulation group will be participating.
Patients diagnosed with Parkinson's who seek treatment at the Clinical School of Physiotherapy of the Federal University of Piauí will receive detailed instructions on the present study.
The physiotherapist responsible for evaluations will explain the objectives of the study, possible treatments, eligibility criteria and potential risks arising from the application of brain stimulation and therapeutic exercises.
Patients who agree to the conditions and sign the consent form may participate in the study.
Participants who meet the eligibility criteria will be included in the study.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
PI
-
Parnaíba, PI, Brazil, 64202020
- Universidade Federal do Piauí
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
46 years to 76 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- medical diagnosis of idiopathic Parkinson's disease present for at least 12 months,
- spontaneous demand for treatment,
- in clinical follow-up and pharmacological treatment by a responsible physician,
- Parkinson's classification of 1.5-3 according to the Hoehn and Yahr scale,
- absence of cardiovascular diseases and musculoskeletal,
- signing of the free and informed consent form.
Exclusion Criteria:
- Use any associated orthopedic device to aid gait or balance control,
- signs of severe dementia (evaluated by the Mini-Mental State Examination - MMSE),
- diagnosis of other neurological disorders (including those of central and peripheral nature)
- previous treatment with tDCS,
- medical diagnosis of psychiatric illnesses with the use of centrally acting medications (depressants)
- the use of pacemakers or other implanted devices.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: anodal tDCS +Exercise Therapy
Anodal tDCS (2mA of intensity, for twenty minutes) over the motor cortex representation of trunk and lower limbs.
Immediately after tDCS application all the patients will participate in an exercise therapy protocol involving balance control, strength,
|
Transcranial direct current stimulation is a modulation technique of neuronal excitability which has very promising results in Parkinson's disease.
In addition to the possibility of increasing the excitability of areas to tDCS, it can also facilitate the execution of the exercises by increasing the excitability of the primary motor cortex and changing the recruitment strategies of the motor units.
Other Names:
Therapeutic exercises will be based on the literature (O'Sullivan and Schmitz 2004, Klamroth et al 2016, Reynolds et al., 2016, Pérez et al 2016, Smania et al., 2010, Pastor et al., 1993, Traub et al., 1980, Schoneburg et al., 2013) Each session will be divided into warm-up exercises; balance and relaxation, with a duration of 50 minutes and a frequency of 3 times a week.
Training progresses and intensifies every two weeks.
The subjects will perform five repeated movements of each exercise, evolving according to the condition of each patient (according to the Hoehn and Yahr staging scale).
Other Names:
|
|
Sham Comparator: Sham tDCS+ Exercise Therapy
Anodal tDCS (2mA of intensity, for twenty minutes but thirdy seconds ON) over the motor cortex representation of trunk and lower limbs.
|
Transcranial direct current stimulation is a modulation technique of neuronal excitability which has very promising results in Parkinson's disease.
In addition to the possibility of increasing the excitability of areas to tDCS, it can also facilitate the execution of the exercises by increasing the excitability of the primary motor cortex and changing the recruitment strategies of the motor units.
Other Names:
Therapeutic exercises will be based on the literature (O'Sullivan and Schmitz 2004, Klamroth et al 2016, Reynolds et al., 2016, Pérez et al 2016, Smania et al., 2010, Pastor et al., 1993, Traub et al., 1980, Schoneburg et al., 2013) Each session will be divided into warm-up exercises; balance and relaxation, with a duration of 50 minutes and a frequency of 3 times a week.
Training progresses and intensifies every two weeks.
The subjects will perform five repeated movements of each exercise, evolving according to the condition of each patient (according to the Hoehn and Yahr staging scale).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From balance
Time Frame: 8 weeks after randomization
|
Balance will be evaluated using a force plate to record center of pressure displacement (COP) in antero-posterior (AP) and Mediolateral (ML) axes in centimeters.
Other variables such as area (cm²), speed AP and ML(cm/s), frequency (Hz) and Entropy (no unit) will be derived from COP displacement.
|
8 weeks after randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From balance
Time Frame: 3 and 6 months after randomization
|
Balance will be evaluated using a force plate to record center of pressure displacement (COP) in antero-posterior (AP) and Mediolateral (ML) axes in centimeters.
Other variables such as area (cm²), speed AP and ML(cm/s), frequency (Hz) and Entropy (no unit) will be derived from COP displacement.
|
3 and 6 months after randomization
|
|
Change From Unified Parkinson´s Disease Rating Scale
Time Frame: 8 weeks, 3 and 6 months after randomization
|
The Unified Parkinson's Disease Rating evaluate is composed of 42 questions, divided into 4 parts: motor symptoms; mental activity, behavior and mood; activities of daily living; complications of drug therapy.
The mental activity, behavior and humor part counts of 4 questions being the score ranging from 0 to 4 totaling 16 points.
The daily life activity part consists of 13 questions that range from 0 to 4 scores totaling 52 points.
The motor symptoms part consists of 14 questions, in which some of them have to be applied independently for each member.
Thus, there are 27 observations that vary the score from 0 to 4, totaling 108 points.
Part of the complications of drug therapy consists of 23 questions in which 4 vary the score from 0 to 4 and 7 questions vary the score from 0 to 1 totaling 23 points.
Thus, the scoring of this scale varies between 0 and 199 in that the higher the score the greater the impairment and the closer to zero the more tendency to normality
|
8 weeks, 3 and 6 months after randomization
|
|
Change From Parkinson Disease Quality of Life
Time Frame: 8 weeks, 3 and 6 months after randomization
|
Parkinson Disease Quality of Life is a questionnaire consists of 37 items, subdivided into four domains: parkinsonian symptoms (14 items), systemic symptoms (7 items), emotional function (7 items) social function (9 items).
The score ranges from 1 (all time), 2 (almost always), 3 (sometimes), 4 (few times) and 5 (never).
The score of each domain is determined by the average of the points of each domain.
The sum of the average score of each domain is made and high scores refers to the individual's better perception regarding his or her quality of life.
|
8 weeks, 3 and 6 months after randomization
|
|
Change in the perception scale of the overall effect
Time Frame: 8 weeks, 3 and 6 months after randomization
|
Perception scale of the overall effect evaluates the level of perception of recovery of the patient in relation to the treatment comparing the beginning of the symptoms with the last days.
It is a numerical scale of 11 points ranging from -5 to +5, being - 5: extremely worse; zero: no modification; and +5: fully recovered, with the highest score representing greater recovery
|
8 weeks, 3 and 6 months after randomization
|
|
Maximal Isometric Voluntary Contraction
Time Frame: 8 weeks, 3 and 6 months after randomization
|
Peak and average force (Kg or Newton) and time to peak (seconds) will be collected during the maximal Isometric contraction of knee extensor muscles.
|
8 weeks, 3 and 6 months after randomization
|
|
Tampa Scale for Kinesiophobia (TSK)
Time Frame: 8 weeks, 3 and 6 months after randomization
|
Irrational, and debilitating fear of movement and activity resulting from a feeling of vulnerability to painful injury or re-injury.
Its a 17-item scale.
|
8 weeks, 3 and 6 months after randomization
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Geriatric Depression Scale (GDS)
Time Frame: 8 weeks, 3 and 6 months after randomization
|
Assessment of emotional function with GDS.
Its a 15 item scale
|
8 weeks, 3 and 6 months after randomization
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2018
Primary Completion (Actual)
December 1, 2019
Study Completion (Actual)
January 15, 2021
Study Registration Dates
First Submitted
February 7, 2018
First Submitted That Met QC Criteria
March 20, 2018
First Posted (Actual)
March 22, 2018
Study Record Updates
Last Update Posted (Actual)
May 3, 2021
Last Update Submitted That Met QC Criteria
April 30, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2.085.438
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
Bezmialem Vakif UniversityRecruitingParkinson Disease | Parkinson | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseTurkey (Türkiye)
-
CND Life SciencesDigestive Disease Associates of CTRecruitingParkinson Disease | Parkinson | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Neuron23 Inc.Roche Diagnostic Ltd.; Qiagen Manchester LimitedRecruitingParkinson Disease | Parkinson | Idiopathic Parkinson Disease | Parkinson Disease, Idiopathic | Early Parkinson Disease (Early PD)United States, Spain, Israel, Poland, Italy, United Kingdom
-
San Francisco Neurology and Sleep CenterNot yet recruitingPARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Haukeland University HospitalUniversity of Bergen; SPARK NSRecruitingParkinson Disease (PD) | Parkinson s DiseaseNorway
-
CND Life SciencesOregon Health and Science UniversityRecruitingParkinson Disease | Parkinson | Parkinson's Disease and Parkinsonism | PARKINSON DISEASE (Disorder)United States
-
Università degli Studi dell'InsubriaUniversidade Nova de Lisboa; Associazione Parkinson Insubria (AsPI), Section... and other collaboratorsRecruitingParkinson Disease | Parkinson | Parkinson Disease, Idiopathic | PARKINSON DISEASE (Disorder)Italy
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
Duke UniversityMedical University of South Carolina; Massachusetts General Hospital; Mayo Clinic and other collaboratorsNot yet recruitingGut Microbiota | Gut Microbiome | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Prodromal Parkinsons DiseaseUnited States
-
ProgenaBiomeWithdrawnParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
Clinical Trials on tDCS
-
Northeastern UniversityMassachusetts General Hospital; National Institute on Aging (NIA)Unknown
-
Hôpital le VinatierCompletedSchizophrenia | Auditory HallucinationsFrance, Tunisia
-
Universidad de AlmeriaSecretaría General de Universidades, Investigación y Tecnología, Junta de...Enrolling by invitationSubstance-Related DisordersSpain
-
Thorsten RudroffTerminatedMultiple Sclerosis | Neuropathic PainUnited States
-
Nachum Soroker, MDUnknown
-
University of MichiganNational Institute of Mental Health (NIMH)Completed
-
New York UniversityRecruiting
-
Xuanwu Hospital, BeijingBeijing Tiantan Hospital; Second Affiliated Hospital of Tsinghua UniversityNot yet recruitingNeuropathic Pain
-
Bambino Gesù Hospital and Research InstituteCompleted
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedMotor Activity | Motor NeuroplasticityUnited States